BioToxTech Co

BioToxTech Co Rule of 40

The Rule of 40 of BioToxTech Co (086040.KQ) as of Oct 21, 2026 is 3.50 %. In the previous year, Rule of 40 was 13.48 % — a change of -74.05% (lower).

Rule of 40

3.50 %

YoY

-74.05%

Last updated:

Rule of 40 of BioToxTech Co is 2025 3.50 % . Rule of 40 of BioToxTech Co was 2024 13.48 % . It decreases by -74.05% lower compared to the previous year.

The BioToxTech Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
6.83 KRW
Jan 1, 2019
-10.18 KRW
Jan 1, 2020
4.26 KRW
Jan 1, 2021
36.50 KRW
Jan 1, 2022
16.61 KRW
Jan 1, 2023
-37.70 KRW
Jan 1, 2024
13.48 KRW
Jan 1, 2025
3.50 KRW
The BioToxTech Co Rule of 40 history
YEARRule of 40YoY
3.50 %-74.05%
13.48 %-135.75%
-37.70 %-327.02%
16.61 %-54.50%
36.50 %+757.48%
4.26 %-141.83%
-10.18 %-248.91%
6.83 %-70.81%
23.41 %-45.00%
42.57 %-379.58%
-15.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Rule of 40 of BioToxTech Co is 3.50 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — BioToxTech Co

All Key Metrics — BioToxTech Co